Hypersensitivity pneumonitis medical therapy

Jump to navigation Jump to search

Hypersensitivity pneumonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypersensitivity pneumonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Hypersensitivity pneumonitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypersensitivity pneumonitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypersensitivity pneumonitis medical therapy

CDC on Hypersensitivity pneumonitis medical therapy

Hypersensitivity pneumonitis medical therapy in the news

Blogs on Hypersensitivity pneumonitis medical therapy

Directions to Hospitals Treating Hypersensitivity pneumonitis

Risk calculators and risk factors for Hypersensitivity pneumonitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The best treatment is to avoid the provoking allergen, as chronic exposure can cause permanent damage. Corticosteroids such as Prednisolone may help to control symptoms but may produce side-effects.

Medical Therapy

  • The mainstay of treatment for HP is:
    • Environmental control/ Antigen exposure control
    • Corticosteroid therapy

Antigen Control

  • Mainstay in treatment is complete control of exposure to antigen.
  • If complete avoidance of antigen exposure cannot be done then the following can be done:
    • Protective equipment can be used to minimize exposure.
    • Personal air purification can be achieved with the use of respirators.
    • Ambient antigen burden can be reduced using dehumidification, mold removal and fungicides.

Corticosteroid therapy

  • Corticosteroid therapy can be used to treat acute symptoms.
  • In severe disease, corticosteroid use can accelerate the initial recovery.
  • Preferred regimen in acute HP: prednisone 0.5-1 mg/kg/day for 7-14 days.
  • Preferred regimen in subacute HP: prednisone 0.5-1 mg/kg/day for 4-8 weeks.
  • Preferred regimen for maintenance : prednisone 10 mg/day.
    • Maintenance dose is only required if the patient cannot be removed from antigen exposure.

Continued therapy should be guided by clinical response, pulmonary function, and radiographic improvement. Maintenance doses are not always required, particularly if the patient is removed from exposure.

References

Template:WH Template:WS